골다골증 치료의 의학약제와 대체 약물의 비교

참고문헌 (69)

1. "Management of osteoporosis in postmenopausal women:2006 position statement of The North American Menopause Society", 13, pp.340~367 (2006)
2. "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis", 333, pp.1437~1443 (1995)
3. "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures:Fracture Intervention Trial Research Group", 348, pp.1531~1541 (1996)
4. "Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures:Results from the Fracture Intervention Trial", 280, pp.2077~2082 (1998)
5. "Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis:a randomized controlled trial", 282, pp.1344~1352 (1999)
6. "Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis" (2000)
7. "Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis", 19, pp.1241~1249 (2004)
8. "Alendronate prevents postmenopausal bone loss in women without osteoporosis: a double-blind, randomized controlled trial", 128, pp.253~261 (1998)
9. "Prevention of postmenopausal bone loss six-year results from the Early Postmenopausal Intervention Cohort Study", 89, pp.4879~4885 (2004)
10. "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis", 333, pp.1437~1443 (1995)
11. "Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD:results from the Fracture Intervention Trial long-term extension", 19, pp.1259~1269 (2004)
12. "Ten years' experience with alendronate for osteoporosis in postmenopausal women", 350, pp.1189~1199
13. "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures:Fracture Intervention Trial Research Group", 348, pp.1531~1541 (1996)
14. "Risedronate increases bone mass in an early postmenopausal population:two years of treatment plus one year of follow-up", 83, pp.396~402 (1998)
15. "Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group", 344, pp.333~340 (2001)
16. "Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis", 19, pp.11~18 (2004)
17. "Seven years of treatment with risedronate in women with postmenopausal osteoporosis", 75, pp.462~468 (2004)
18. "Severely suppressed bone turnover:a potential complication of alendronate therapy", 90, pp.1294~1304 (2005)
19. "Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators", 282, pp.637~645 (1999)
20. "Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial", 87, pp.3609~3617 (2002)
21. "The effect of raloxifene on risk of breast cancer in postmenopausal women results from the MORE randomized trial Multiple Outcomes of Raloxifene Evaluation", 281, pp.2189~2197 (1999)
22. "Continuing outcomes relevant to Evista breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene", 96, pp.1751~1761 (2004)
23. "Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial", 295, pp.2727~2741 (2006)
24. "Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation", 104, pp.837~844 (2004)
25. "Raloxifene Use for The Heart Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women", 355, pp.125~137 (2006)
26. "Meta-analyses of therapies for postmenopausal osteoporosis Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women", 23, pp.529~539 (2002)
27. "Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen", Progestin Interventions (PEPI) trial, 1996, pp.276, 1389~1396
28. "Effects of estrogen plus progestin on risk of fracture and bone mineral density:the Women's Health Initiative randomized trial", 290, pp.1729~1738 (2003)
29. "Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women", 287, pp.2668~2676 (2002)
30. "Ultralow- dose micronized 17beta-estradiol and bone density and bone metabolism in older women:a randomized controlled trial", 290, pp.1042~1048 (2003)
31. "Effects of ultralow-dose transdermal estradiol on bone mineral density:a randomized clinical trial", 104, pp.443~451 (2004)
32. "Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial", 289, pp.3243~3253 (2003)
33. "Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial", 289, pp.2673~2684 (2003)
34. "Estrogen plus progestin and the risk of coronary heart disease", 349, pp.523~534 (2003)
35. "Estrogen plus progestin and risk of venous thrombosis", 292, pp.1573~1580 (2004)
36. "Recommendations for estrogen and progestogen use in peri-and postmenopausal women:October 2004 position statement of The North American Menopause Society", 11, pp.589~600 (2004)
37. "A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis the Prevent Recurrence of Osteoporotic Fractures Study", 109, pp.267~276 (2000)
38. "Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures", 11, pp.205~9 (1989)
39. "Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study", 15, pp.284~289 (1999)
40. "Effect of parathyroid hormone on fractures and bone mineral density in postmenopausal women with osteoporosis", 344, pp.1434~1441 (2001)
41. "Alendronate and estrogen effect in postmenopausal women with low bone mineral density. Alendronate", Estrogen Study Group, 2000, pp.85, 720~726
42. "Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women", 86, pp.1890~1897 (2001)
43. "Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis", 350, pp.550~555 (1997)
44. "One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis", 353, pp.555~565 (2005)
45. "Soy milk or progesterone for prevention of bone loss-a 2year randomized, placebo-controlled trial", 43, pp.246~257 (2004)
46. "Health potential of soy isoflavones for menopausal women", 2, pp.489~504 (1999)
47. "Dietary soy isoflavones and bone mineral density:results from the study of women's health across the nation", 155, pp.746~754 (2002)
48. "Soy protein and isoflavones: ther effects on blood lipids and bone density in postmenopausal women", 68, pp.1375~1379 (1998)
49. "The effect of isoflavones extracted from red clover on lipid and bone metabolism", 8, pp.4740~4747 (2001)
50. "Effects of genistein and hormone- replacement therapy on bone loss in early post-menopausal women:a randomized double-blind placebo controlled study", 17, pp.1904~1912 (2002)
51. "Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial", 292, pp.65~74 (2004)
52. "Soy isoflavones have favorable effect on bone loss in Chinese postmenopausal women with lower bone mass: a double-blind randomized, controlled trial", 88, pp.4740~4747 (2003)
53. "The effect of soy protein isolate on bone metabolism", 11, pp.290~298 (2004)
54. "Evidence of estrogenic effect by the three-month intervention of isoflavone on vaginal maturation and bone metabolism in early postmenopausal women", 50, pp.613~619 (2003)
55. "Preventive effects of a Chinese herbal medicine on bone loss in ovariectomized rats", 15, pp.25~28 (2001)
56. "Preventive effects of a herbal medicine on bone loss in rats treated with a GnRH agonist", 143, pp.139~142 (2000)
57. "A Japanese herbal medicine, Chujo-to, has a beneficial effect on osteoporosis in rats", 13, pp.14~19 (1999)
58. "Bone protecting effect of safflower seeds in ovariectomized rats", 71, pp.88~94 (2002)
59. "Dehydroepiandrosterone (DHEA) DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue", 97, pp.4279~4284 (2000)
60. "The biological role of strontium", 35, pp.583~588 (2004)
61. "Mechanisms of action and therapeutic potential of strontium in bone", 69, pp.121~129 (2001)
62. "In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation", 450, pp.11~17 (2002)
63. "The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro", 18, pp.517~523 (1996)
64. "Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats", 19, pp.2012~2020 (2004)
65. "The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis", 350, pp.459~468 (2004)
66. "Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) study", 90, pp.2816~2822 (2005)
67. "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation", 93, pp.165~176 (1998)
68. "A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women", 19, pp.1059~1066 (2004)
69. "Denosumab in postmenopausal women with low bone mineral density", pp.821~831 (2006)

관련 논문AI추천